JNK inhibitor (Kd values are 87, 360 and 390 nM for JNK3, JNK2 and JNK1, respectively). Inhibits LPS-induced proinflammatory cytokine and nitric oxide production in vitro. Attenuates collagen-induced arthritis severity and inhibits murine delayed-type hypersensitivity in vivo. Anti-inflammatory and immunosuppressive. Also releases NO upon metabolism by liver microsomes.
Schepetkin et al (2015) Anti-Inflammatory effects and joint protection in collagen-induced arthritis after treatment with IQ-1S, a selective c-Jun N-terminal kinase Inhibitor. J.Pharmacol.Exp.Ther. 353 505 PMID:25784649 |Schepetkin et al (2012) Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors. Mol.Pharmacol. 81 832 PMID:22434859 |Atochin et al (2016) A novel dual NO-donating oxime and c-Jun N-terminal kinase inhibitor protects against cerebral ischemia-reperfusion injury in mice. Neurosci.Lett. 618 45 PMID:26923672